Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.02 USD | -0.21% | +0.19% | -12.34% |
May. 20 | Exelixis Settles Cabometyx Patent Litigation with Cipla | MT |
May. 14 | Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.34% | 6.13B | |
+8.47% | 115B | |
+13.29% | 107B | |
-13.63% | 22.31B | |
-3.67% | 21.6B | |
-5.96% | 18.23B | |
-39.93% | 17.62B | |
+7.45% | 14.26B | |
+33.91% | 12.37B | |
-27.47% | 8.28B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Citigroup Initiates Exelixis at Buy Rating With $31 Price Target